What is Crinetics Pharmaceuticals's G&A?

Crinetics Pharmaceuticals (CRNX) reported G&A of $50.83M in Q1 2026.

How has Crinetics Pharmaceuticals's G&A changed year-over-year?

Crinetics Pharmaceuticals's G&A increased by 43.1% year-over-year, from $35.53M to $50.83M.

What is the long-term trend for Crinetics Pharmaceuticals's G&A?

Over 3 years (2021 to 2024), Crinetics Pharmaceuticals's G&A has grown at a 59.6% compound annual growth rate (CAGR), from $24.53M to $99.74M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Crinetics Pharmaceuticals CRNX G&A

G&A at other companies

Viking TherapeuticsVKTX

$13.98M-0.7%

Protagonist TherapeuticsPTGX

$13.28M+13.1%

Erasca, Inc.ERAS

$10.65M+10.2%

CG OncologyCGON

$20.78M+40.5%

Lantheus HoldingsLNTH

$57.53M+1.3%

Nuvalent, Inc.NUVL

$35.8M+75.5%

Other financials

Income statement

See full

Revenue$10.7M+2,873%

Gross profit$10.5M+2,818%

Operating income-$140.4M-26.0%

Net income-$127.8M-32.1%

EPS (diluted)-$1.23-18.3%

Balance sheet

See full

Cash & equivalents$115.1M+20.1%

Total debt$47.9M-5.8%

Total equity$1.3B+2.1%

Total assets$1.4B+2.9%

Cash flow

See full

Operating cash flow-$124.7M-41.0%

CapEx$820.0K-33.8%

Free cash flow-$125.5M-40.0%

Valuation

See full

Market cap$3.79B+21.9%

Profitability

See full

Gross margin150%-15.6pp

Operating margin-3,020.3%-1,463pp

Net margin-2,747.2%-1,328pp

FCF margin-2,321.7%-1,122pp

Returns & leverage

See full

Return on equity-39.2%+14.5pp

Debt / equity0×0.0×

Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Crinetics Pharmaceuticals's G&A?: Crinetics Pharmaceuticals (CRNX) reported G&A of $50.83M in Q1 2026.
How has Crinetics Pharmaceuticals's G&A changed year-over-year?: Crinetics Pharmaceuticals's G&A increased by 43.1% year-over-year, from $35.53M to $50.83M.
What is the long-term trend for Crinetics Pharmaceuticals's G&A?: Over 3 years (2021 to 2024), Crinetics Pharmaceuticals's G&A has grown at a 59.6% compound annual growth rate (CAGR), from $24.53M to $99.74M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.